2nd Propaedeutic Department of Internal Medicine ATTIKON University Hospital National and Kapodistrian University of Athens School of Medicine Athens Greece

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Dana Farber Cancer Institute Harvard Medical School Boston MA USA

Department of Medical and Surgical Sciences University of Bologna Bologna Italy

Department of Medical Oncology San Camillo Forlanini Hospital Rome Italy

Department of Molecular Medicine Sapienza University Rome Italian Pasteur Institute Cenci Bolognetti Foundation Rome Italy

Department of Oncology and Radiotherapeutics Faculty of Medicine and University Hospital in Pilsen Charles University Pilsen Czech Republic

Department of Urology Saitama Medical Center Saitama Medical University Saitama Japan

Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italy

Medical Oncology Unit University Hospital of Parma Department of Medicin and Surgery University of Parma Parma Italy

Oncology Unit Macerata Hospital Macerata Italy

Zobrazit více v PubMed

Powles, T. B. et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann. Oncol. 34 (Suppl. 2), S1340 (2023). DOI

Chikuma, S. et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell energy? in vivo. J. Immunol. 182, 6682–6689 (2009). PubMed DOI

Milella, M. et al. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. Br. J. Cancer 79, 770–779 (1999). PubMed DOI PMC

Sakatani, T. et al. IFN-gamma expression in the tumor microenvironment and CD8-positive tumor-infiltrating lymphocytes as prognostic markers in urothelial cancer patients receiving pembrolizumab. Cancers 14, 263 (2022). PubMed DOI PMC

Baker, S. C. et al. The urothelial transcriptomic response to interferon gamma: implications for bladder cancer prognosis and immunotherapy. Cancers 14, 5295 (2022). PubMed DOI PMC

Liu, Y. et al. Role of nectin-4 protein in cancer (Review). Int. J. Oncol. 59, 93 (2021). PubMed DOI

Chen, Z. et al. Comprehensive analysis revealed that CDKN2A is a biomarker for immune infiltrates in multiple cancers. Front. Cell Dev. Biol. 9, 808208 (2021). PubMed DOI PMC

Challita-Eid, P. M. et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 76, 3003–3013 (2016). PubMed DOI

Gray, E. et al. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. J. Immunother. Cancer 11, e007572 (2023). PubMed DOI PMC

Ganguli, N., Kumari, P., Dash, S. & Samanta, D. Molecular and structural basis of TIGIT: nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy. Biochem. Biophys. Res. Commun. 677, 31–37 (2023). PubMed DOI